These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33471673)

  • 1. Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks.
    Chen TH; Wang CC; Liu CH; Hsiao CC; Chen ST; Liu FH; Ho MY; Li YR
    Endocr Pract; 2020 Aug; 26(8):818-829. PubMed ID: 33471673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
    Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
    Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
    Rys P; Wojciechowski P; Rogoz-Sitek A; Niesyczyński G; Lis J; Syta A; Malecki MT
    Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.
    Damci T; Emral R; Svendsen AL; Balkir T; Vora J;
    BMC Endocr Disord; 2014 Jul; 14():61. PubMed ID: 25048824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes.
    Heintjes EM; Thomsen TL; Penning-van Beest FJ; Christensen TE; Herings RM
    Adv Ther; 2010 Apr; 27(4):211-22. PubMed ID: 20449697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective.
    Permsuwan U; Thavorn K; Dilokthornsakul P; Saokaew S; Chaiyakunapruk N
    J Med Econ; 2017 Sep; 20(9):991-999. PubMed ID: 28649943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study.
    Papademetriou V; Nylen ES; Doumas M; Probstfield J; Mann JFE; Gilbert RE; Gerstein HC
    Am J Med; 2017 Dec; 130(12):1465.e27-1465.e39. PubMed ID: 28842165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.
    Chen DY; Li YR; Mao CT; Tseng CN; Hsieh IC; Hung MJ; Chu PH; Wang CH; Wen MS; Cherng WJ; Chen TH
    J Diabetes Investig; 2020 Jan; 11(1):110-124. PubMed ID: 31115964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks.
    Kao YC; Chen TH; Liu CH; Hwang JS; Hsiao CC; Lin YS; Mao CT; Hung MJ; Li YR
    Sci Rep; 2021 Mar; 11(1):6697. PubMed ID: 33758291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study.
    Kuo S; Yang CT; Wu JS; Ou HT
    Diabetes Obes Metab; 2019 Feb; 21(2):312-320. PubMed ID: 30187666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
    White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
    Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
    Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
    Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
    Wang SH; Chen DY; Lin YS; Mao CT; Tsai ML; Hsieh MJ; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    PLoS One; 2015; 10(6):e0131122. PubMed ID: 26115092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes.
    Ramanathan K; Abel JG; Park JE; Fung A; Mathew V; Taylor CM; Mancini GBJ; Gao M; Ding L; Verma S; Humphries KH; Farkouh ME
    J Am Coll Cardiol; 2017 Dec; 70(24):2995-3006. PubMed ID: 29241487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
    Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
    Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
    Elharram M; Sharma A; White W; Bakris G; Rossignol P; Mehta C; Ferreira JP; Zannad F
    Am Heart J; 2020 Nov; 229():40-51. PubMed ID: 32916607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.
    Seferovic JP; Bentley-Lewis R; Claggett B; Diaz R; Gerstein HC; Køber LV; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Pfeffer MA
    J Diabetes Res; 2018; 2018():1631263. PubMed ID: 30648112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of the atherogenic index of plasma in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Ma X; Sun Y; Cheng Y; Shen H; Gao F; Qi J; Yang L; Wang Z; Shi D; Liu Y; Liu X; Zhou Y
    Lipids Health Dis; 2020 Nov; 19(1):240. PubMed ID: 33198752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.